Clinical trial TAS-120-202
A Phase 2 Study of TAS-120 in Patients with Specific FGFR (Fibroblast Growth Factor Receptor) Aberrations
| Organ | Multiple |
|---|---|
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | TAIHO Pharmaceutical Co. Ltd |
| EudraCT Identifier | 2019-004084-49 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04189445 |
| Inclusion criteria | Mutation FGFR(1-4) |
| Last update |